Therapeutic Focus

Neotropix™ Inc. develops and commercializes systemically deliverable oncolytic viruses for the treatment of solid tumors. Capitalizing on its unique sources of naturally occurring viruses that selectively target tumors, the Company has the knowledge and skills to translate these discoveries into commercial products. Neotropix is committed to making a difference in the lives of cancer patients.

The concept of using an oncolytic virus to treat cancer has significant advantages over other types of cancer therapies being utilized or tested today. First, many viruses have exquisite selectivity, or tropism, to infect and kill only certain types of cells. Second, a single systemic administration of an oncolytic virus should minimally infect all permissive metastatic tumor masses, known and unknown, as well as permissive cancer cells circulating in the bloodstream. Third, virotherapy is the only treatment for solid cancers that will amplify to the required dose at the pharmacologically desired site - inside the tumor mass. Thus, oncolytic virotherapy should be more efficacious, less toxic, require less starting material and fewer, if any, repeat doses than traditional chemotherapy, radiation, or monoclonal antibody therapy.